← All trials
NCT04347681
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 12, 2020
- Primary completion
- Dec 31, 2020
- Completion date
- Apr 11, 2021
- First posted
- Apr 15, 2020
- Last posted
- Apr 15, 2020
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- King Fahad Medical CityLead sponsor
- King Abdul-Aziz UniversityCollaborator
- King Saud UniversityCollaborator
- Taibah UniversityCollaborator
- Johns Hopkins UniversityCollaborator
- King Fahad Medical CityOverall official - principal investigator
- King Fahad Medical CityCollaborator
- King Faisal Specialist HospitalCollaborator
- King Khaled Eye Specialist HospitalCollaborator
- Qatif Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.